Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30

OncoImmunology

Volumn 5, Issue 1, 2016, Pages

  Kellner, Christian ^a   Günther, Andreas ^a   Humpe, Andreas ^a   Repp, Roland ^a   Klausz, Katja ^a   Derer, Stefanie ^a   Valerius, Thomas ^a   Ritgen, Matthias ^a   Brüggemann, Monika ^a   van de Winkel, Jan G J ^b,c   Parren, Paul W H I ^b,d,e   Kneba, Michael ^a   Gramatzki, Martin ^a   Peipp, Matthias ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b GENMAB   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ADCC; Antibody; CD20; NK cells; NKG2D; NKp30

Indexed keywords

CD19 ANTIGEN; CD3 ANTIBODY; CD56 ANTIBODY; CD56 ANTIGEN; CD69 ANTIGEN; DARATUMUMAB; FC RECEPTOR; FC RECEPTOR IIIA; IMMUNOGLOBULIN KAPPA CHAIN; MEMBRANE ANTIGEN; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2D; RITUXIMAB; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; CAPILLARY ELECTROPHORESIS; CELL ACTIVATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DRUG POTENCY; DRUG POTENTIATION; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; LYMPHOMA; LYMPHOMA CELL; NATURAL KILLER CELL;

EID: 84954431202     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1058459     Document Type: Article

References (47)

1. Oldham RK, Dillman RO. Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol 2008; 26:1774-1777; PMID:18398141; http://dx. doi. org/10. 1200/JCO. 2007. 15. 7438
2. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278-287; PMID:22437872; http://dx. doi. org/10. 1038/nrc3236
3. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6:443-446; PMID:10742152; http://dx. doi. org/10. 1038/74704
4. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005; 310:1510-1512; PMID:16322460; http:// dx. doi. org/10. 1126/science. 1118948
5. de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL, Martens A, Verbeek JS, Parren PWHI, van de Winkel JGJ et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res 2010; 70:3209-3217; PMID:20354182; http://dx. doi. org/10. 1158/0008-5472. CAN-09-4109
6. Hubert P, Heitzmann A, Viel S, Nicolas A, Sastre-Garau X, Oppezzo P, Pritsch O, Osinaga E, Amigorena S. Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy. Cancer Res 2011; 71:5134-5143; PMID:21697279; http://dx. doi. org/10. 1158/0008-5472. CAN-10-4222
7. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21:3940-3947; PMID:12975461; http://dx. doi. org/10. 1200/ JCO. 2003. 05. 013
8. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neupositive metastatic breast cancer. J Clin Oncol 2008; 26:1789-1796; PMID:18347005; http://dx. doi. org/ 10. 1200/JCO. 2007. 14. 8957
9. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-758; PMID:11806974; http://dx. doi. org/10. 1182/blood. V99. 3. 754
10. Persky DO, Dornan D, Goldman BH, Braziel RM, Fisher RI, Leblanc M, Maloney DG, Press OW, Miller TP, Rimsza LM. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica 2012; 97:937-942; PMID:22271896; http://dx. doi. org/10. 3324/ haematol. 2011. 050419
11. Bowles JA, Wang SY, Link BK, Allan B, Beuerlein G, Campbell MA, Marquis D, Ondek B, Wooldridge JE, Smith BJ et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006; 108:2648-2654; PMID:16825493; http:// dx. doi. org/10. 1182/blood-2006-04-020057
12. Seidel UJ, Schlegel P, Lang P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol 2013; 4:76; PMID:23543707; http://dx. doi. org/10. 3389/fimmu. 2013. 00076
13. Tarek N, Le Luduec JB, Gallagher MM, Zheng J, Venstrom JM, Chamberlain E, Modak S, Heller G, Dupont B, Cheung NK et al. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest 2012; 122:3260-3270; PMID:22863621; http:// dx. doi. org/10. 1172/JCI62749
14. Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by antitumor antibodies: an engineer's perspective. Drug Discov Today 2007; 12:898-910; PMID:17993407; http://dx. doi. org/10. 1016/j. drudis. 2007. 08. 009
15. Kellner C, Derer S, Valerius T, Peipp M. Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions. Methods 2014; 65:105-113; PMID:23851282; http://dx. doi. org/ 10. 1016/j. ymeth. 2013. 06. 036
16. Kohrt HE, Houot R, Marabelle A, Cho HJ, Osman K, Goldstein M, Levy R, Brody J. Combination strategies to enhance antitumor ADCC. Immunotherapy 2012; 4:511-527; PMID:22642334; http://dx. doi. org/ 10. 2217/imt. 12. 38
17. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331:44-49; PMID:21212348; http://dx. doi. org/10. 1126/science. 1198687
18. Vivier E, Nunes JA, Vely F. Natural killer cell signaling pathways. Science 2004; 306:1517-1519; PMID:15567854; http://dx. doi. org/10. 1126/ science. 1103478
19. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006; 107:159-166; PMID:16150947; http://dx. doi. org/10. 1182/blood-2005-04-1351
20. Bryceson YT, Ljunggren HG, Long EO. Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood 2009; 114:2657-2666; PMID:19628705; http://dx. doi. org/10. 1182/blood-2009-01-201632
21. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Muller A, Pachynski R, Czerwinski D, Coutre S et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011; 117:2423-2432; PMID:21193697; http://dx. doi. org/10. 1182/blood-2010-08-301945
22. Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng WK, Clarke MF, Carlson RW et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012; 122:1066-1075; PMID:22326955; http:// dx. doi. org/10. 1172/JCI61226
23. Binyamin L, Alpaugh RK, Hughes TL, Lutz CT, Campbell KS, Weiner LM. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J Immunol 2008; 180:6392-6401; PMID:18424763; http://dx. doi. org/10. 4049/ jimmunol. 180. 9. 6392
24. Kohrt HE, Thielens A, Marabelle A, Sagiv-Barfi I, Sola C, Chanuc F, Fuseri N, Bonnafous C, Czerwinski D, Rajapaksa A et al. Anti-KIR antibody enhancement of antilymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 2014; 123:678-686; PMID:24326534; http://dx. doi. org/ 10. 1182/blood-2013-08-519199
25. von Strandmann EP, Hansen HP, Reiners KS, Schnell R, Borchmann P, Merkert S, Simhadri VR, Draube A, Reiser M, Purr I et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 2006; 107:1955-1962; PMID:16210338; http://dx. doi. org/10. 1182/ blood-2005-05-2177
26. Kellner C, Gramatzki M, Peipp M. Promoting natural killer cell functions by recombinant immunoligands mimicking an induced self phenotype. Oncoimmunology 2013; 2: e24481; PMID:23894708; http://dx. doi. org/10. 4161/onci. 24481
27. Stamova S, Cartellieri M, Feldmann A, Bippes CC, Bartsch H, Wehner R, Schmitz M, von Bonin M, Bornhauser M, Ehninger G et al. Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells. Leukemia 2011; 25:1053-1056; PMID:21415850; http://dx. doi. org/10. 1038/leu. 2011. 42
28. Vyas M, Koehl U, Hallek M, Strandmann EP. Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer. Trends Mol Med 2014; 20:72-82; PMID:24268686; http://dx. doi. org/ 10. 1016/j. molmed. 2013. 10. 006
29. Kellner C, Maurer T, Hallack D, Repp R, van de Winkel JGJ, Parren PWHI, Valerius T, Humpe A, Gramatzki M, Peipp M. Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity. J Immunol 2012; 189:5037-5046; PMID:23066150; http:// dx. doi. org/10. 4049/jimmunol. 1201321
30. Kellner C, Hallack D, Glorius P, Staudinger M, Mohseni Nodehi S, de Weers M, van de Winkel JGJ, Parren PWHI, Stauch M, Valerius T et al. Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity. Leukemia 2012; 26:830-834; PMID:22005785; http://dx. doi. org/ 10. 1038/leu. 2011. 288
31. Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, Haldeman B, Ostrander CD, Kaifu T, Chabannon C et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009; 206:1495-1503; PMID:19528259; http://dx. doi. org/10. 1084/ jem. 20090681
32. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001; 14:123-133; PMID:11239445; http://dx. doi. org/ 10. 1016/S1074-7613(01)00095-4
33. Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL, Phillips JH. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999; 285:730-732; PMID:10426994; http://dx. doi. org/ 10. 1126/science. 285. 5428. 730
34. Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, Morelli L, Marcenaro E, Accame L, Malaspina A, Biassoni R et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999; 190:1505-1516; PMID:10562324; http://dx. doi. org/10. 1084/ jem. 190. 10. 1505
35. Farnault L, Sanchez C, Baier C, Le Treut T, Costello RT. Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications. Clin Dev Immunol 2012; 2012:421702; PMID:22899948; http://dx. doi. org/ 10. 1155/2012/421702
36. Peipp M, Lammerts van Bueren JJ, Schneider-Merck T, Bleeker WW, Dechant M, Beyer T, Repp R, van Berkel PH, Vink T, van de Winkel JG et al. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 2008; 112:2390-2399; PMID:18566325; http://dx. doi. org/ 10. 1182/blood-2008-03-144600
37. Derer S, Glorius P, Schlaeth M, Lohse S, Klausz K, Muchhal U, Desjarlais JR, Humpe A, Valerius T, PeippM. Increasing FcgammaRIIa affinity of an FcgammaRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity. MAbs 2014; 6:409-421; PMID:24492248; http://dx. doi. org/10. 4161/mabs. 27457
38. Lu H, Yang Y, Gad E, Inatsuka C, Wenner CA, Disis ML, Standish LJ. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clin Cancer Res 2011; 17:6742-6753; PMID:21918170; http://dx. doi. org/10. 1158/1078-0432. CCR-11-1142
39. Lu H, Dietsch GN, Matthews MA, Yang Y, Ghanekar S, Inokuma M, Suni M, Maino VC, Henderson KE, Howbert JJ et al. VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res 2012; 18:499-509; PMID:22128302; http://dx. doi. org/10. 1158/1078-0432. CCR-11-1625
40. Delahaye NF, Rusakiewicz S, Martins I, Menard C, Roux S, Lyonnet L, Paul P, Sarabi M, Chaput N, Semeraro M et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 2011; 17:700-707; PMID:21552268; http://dx. doi. org/10. 1038/nm. 2366
41. Deguine J, Breart B, Lemaitre F, Bousso P. Cutting edge: tumor-targeting antibodies enhance NKG2Dmediated NK cell cytotoxicity by stabilizing NK celltumor cell interactions. J Immunol 2012; 189:5493-5497; PMID:23183896; http://dx. doi. org/10. 4049/ jimmunol. 1202065
42. Larbouret C, Gaborit N, Chardes T, Coelho M, Campigna E, Bascoul-Mollevi C, Mach JP, Azria D, Robert B, Pelegrin A. In pancreatic carcinoma, dual EGFR/ HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption. Neoplasia 2012; 14:121-130; PMID:AMBIGUOUS; http://dx. doi. org/ 10. 1593/neo. 111602
43. Klitgaard JL, Koefoed K, Geisler C, Gadeberg OV, Frank DA, Petersen J, Jurlander J, Pedersen MW. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells. Br J Haematol 2013; 163:182-193; PMID:23927424; http:// dx. doi. org/10. 1111/bjh. 12503
44. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89:4285-4289; PMID:1350088; http:// dx. doi. org/10. 1073/pnas. 89. 10. 4285
45. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186:1840-1848; PMID:21187443; http://dx. doi. org/10. 4049/jimmunol. 1003032
46. Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, Akramiene D, Dechant M, Fey GH, van Berkel PH et al. Combined Fc-protein-and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. J Immunol Methods 2011; 373:67-78; PMID:21855548; http://dx. doi. org/10. 1016/j. jim. 2011. 08. 003
47. Chou TC, Talalay P. Quantitative analysis of doseeffect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55; PMID:6382953; http://dx. doi. org/10. 1016/ 0065-2571(84)90007-4